Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
345 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Endometrial Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Endometrial Cancer - Pipeline Review, H1 2016', provides an overview of the Endometrial Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer - The report reviews pipeline therapeutics for Endometrial Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Endometrial Cancer therapeutics and enlists all their major and minor projects - The report assesses Endometrial Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Endometrial Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Endometrial Cancer Overview 9 Therapeutics Development 10 Pipeline Products for Endometrial Cancer - Overview 10 Pipeline Products for Endometrial Cancer - Comparative Analysis 11 Endometrial Cancer - Therapeutics under Development by Companies 12 Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes 15 Endometrial Cancer - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Endometrial Cancer - Products under Development by Companies 19 Endometrial Cancer - Products under Investigation by Universities/Institutes 23 Endometrial Cancer - Companies Involved in Therapeutics Development 24 Ability Pharmaceuticals, S.L. 24 Advenchen Laboratories, LLC 25 Aeterna Zentaris Inc. 26 Arno Therapeutics, Inc. 27 ArQule, Inc. 28 AstraZeneca Plc 29 AVEO Pharmaceuticals, Inc. 30 BeiGene, Ltd. 31 BioNTech AG 32 Boehringer Ingelheim GmbH 33 Bristol-Myers Squibb Company 34 Cellceutix Corporation 35 Critical Outcome Technologies Inc. 36 Eisai Co., Ltd. 37 Eli Lilly and Company 38 Esperance Pharmaceuticals, Inc. 39 Exelixis, Inc. 40 Galena Biopharma, Inc. 41 Genmab A/S 42 GlaxoSmithKline Plc 43 Gradalis Inc. 44 Horizon Pharma Plc 45 ImmunoGen, Inc. 46 Incyte Corporation 47 Karyopharm Therapeutics, Inc. 48 Medivation, Inc. 49 Merck & Co., Inc. 50 Merck KGaA 51 Millennium Pharmaceuticals, Inc. 52 Novartis AG 53 OncoHoldings, Inc. 54 Otsuka Holdings Co., Ltd. 55 Pfizer Inc. 56 Pharma Mar, S.A. 57 Pharmsynthez 58 Pivot Pharmaceuticals Inc 59 Puma Biotechnology, Inc. 60 Sanofi 61 Shenogen Pharma Group Ltd. 62 Synthon Holdings BV 63 Vertex Pharmaceuticals Incorporated 64 Vyriad 65 Endometrial Cancer - Therapeutics Assessment 66 Assessment by Monotherapy Products 66 Assessment by Combination Products 67 Assessment by Target 68 Assessment by Mechanism of Action 73 Assessment by Route of Administration 77 Assessment by Molecule Type 79 Drug Profiles 81
List of Tables
Number of Products under Development for Endometrial Cancer, H1 2016 14 Number of Products under Development for Endometrial Cancer - Comparative Analysis, H1 2016 15 Number of Products under Development by Companies, H1 2016 16 Number of Products under Development by Companies, H1 2016 (Contd..1) 17 Number of Products under Development by Companies, H1 2016 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H1 2016 19 Comparative Analysis by Late Stage Development, H1 2016 20 Comparative Analysis by Clinical Stage Development, H1 2016 21 Comparative Analysis by Early Stage Development, H1 2016 22 Products under Development by Companies, H1 2016 23 Products under Development by Companies, H1 2016 (Contd..1) 24 Products under Development by Companies, H1 2016 (Contd..2) 25 Products under Development by Companies, H1 2016 (Contd..3) 26 Products under Investigation by Universities/Institutes, H1 2016 27 Endometrial Cancer - Pipeline by Ability Pharmaceuticals, S.L., H1 2016 28 Endometrial Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 29 Endometrial Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016 30 Endometrial Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016 31 Endometrial Cancer - Pipeline by ArQule, Inc., H1 2016 32 Endometrial Cancer - Pipeline by AstraZeneca Plc, H1 2016 33 Endometrial Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 34 Endometrial Cancer - Pipeline by BeiGene, Ltd., H1 2016 35 Endometrial Cancer - Pipeline by BioNTech AG, H1 2016 36 Endometrial Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 37 Endometrial Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 38 Endometrial Cancer - Pipeline by Cellceutix Corporation, H1 2016 39 Endometrial Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 40 Endometrial Cancer - Pipeline by Eisai Co., Ltd., H1 2016 41 Endometrial Cancer - Pipeline by Eli Lilly and Company, H1 2016 42 Endometrial Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016 43 Endometrial Cancer - Pipeline by Exelixis, Inc., H1 2016 44 Endometrial Cancer - Pipeline by Galena Biopharma, Inc., H1 2016 45 Endometrial Cancer - Pipeline by Genmab A/S, H1 2016 46 Endometrial Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 47 Endometrial Cancer - Pipeline by Gradalis Inc., H1 2016 48 Endometrial Cancer - Pipeline by Horizon Pharma Plc, H1 2016 49 Endometrial Cancer - Pipeline by ImmunoGen, Inc., H1 2016 50 Endometrial Cancer - Pipeline by Incyte Corporation, H1 2016 51 Endometrial Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 52 Endometrial Cancer - Pipeline by Medivation, Inc., H1 2016 53 Endometrial Cancer - Pipeline by Merck & Co., Inc., H1 2016 54 Endometrial Cancer - Pipeline by Merck KGaA, H1 2016 55 Endometrial Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 56 Endometrial Cancer - Pipeline by Novartis AG, H1 2016 57 Endometrial Cancer - Pipeline by OncoHoldings, Inc., H1 2016 58 Endometrial Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 59 Endometrial Cancer - Pipeline by Pfizer Inc., H1 2016 60 Endometrial Cancer - Pipeline by Pharma Mar, S.A., H1 2016 61 Endometrial Cancer - Pipeline by Pharmsynthez, H1 2016 62 Endometrial Cancer - Pipeline by Pivot Pharmaceuticals Inc, H1 2016 63 Endometrial Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016 64 Endometrial Cancer - Pipeline by Sanofi, H1 2016 65 Endometrial Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2016 66 Endometrial Cancer - Pipeline by Synthon Holdings BV, H1 2016 67 Endometrial Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 68 Endometrial Cancer - Pipeline by Vyriad, H1 2016 69 Assessment by Monotherapy Products, H1 2016 70 Assessment by Combination Products, H1 2016 71 Number of Products by Stage and Target, H1 2016 73 Number of Products by Stage and Mechanism of Action, H1 2016 78 Number of Products by Stage and Route of Administration, H1 2016 82 Number of Products by Stage and Molecule Type, H1 2016 84 Endometrial Cancer Therapeutics - Recent Pipeline Updates, H1 2016 218 Endometrial Cancer - Dormant Projects, H1 2016 332 Endometrial Cancer - Dormant Projects (Contd..1), H1 2016 333 Endometrial Cancer - Dormant Projects (Contd..2), H1 2016 334 Endometrial Cancer - Discontinued Products, H1 2016 335
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
